原发性肝癌介入治疗研究现状及展望
Research Status and Future Prospects of Interventional Therapy for Primary Liver Cancer
摘要: 肝癌是全球范围内发病率和死亡率均较高的恶性肿瘤之一，尤其在中国，由于慢性乙型病毒性肝炎的高流行率，肝癌的负担尤为严重。介入治疗作为肝癌综合治疗的重要组成部分，在无法手术切除的中晚期肝癌患者中发挥着关键作用。本文综述了肝癌介入治疗的研究现状，包括经动脉化疗栓塞(TACE)、射频消融(RFA)、经动脉放射性栓塞(TARE)等技术的进展、适应症、疗效及局限性，并探讨了未来发展方向。
Abstract: Liver cancer is one of the most prevalent malignancies globally, characterized by high morbidity and mortality rates. Particularly in China, the burden of liver cancer is exacerbated by the high prevalence of chronic hepatitis B virus infection. As a crucial component of comprehensive liver cancer treatment, interventional therapy plays a pivotal role in managing patients with unresectable intermediate and advanced-stage liver cancer. This article reviews the current research landscape of interventional therapy for liver cancer, encompassing advancements, indications, efficacy, and limitations of techniques such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and trans- arterial radioembolization (TARE). Furthermore, it explores future directions in this field.
文章引用：邓晶今. 原发性肝癌介入治疗研究现状及展望[J]. 临床医学进展, 2025, 15(6): 102-105. https://doi.org/10.12677/acm.2025.1561703

参考文献

[1] Zheng, R., Zhang, S., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. [Google Scholar] [CrossRef] [PubMed]
[2] Han, B., Zheng, R., Zeng, H., Wang, S., Sun, K., Chen, R., et al. (2024) Cancer Incidence and Mortality in China, 2022. Journal of the National Cancer Center, 4, 47-53. [Google Scholar] [CrossRef] [PubMed]
[3] 滕皋军. 肝癌介入治疗的精准选择与合理应用[J]. 中国实用外科杂志, 2024, 44(9): 992-995.
[4] 范卫君. 2023原发性肝癌血管介入治疗研究现状概述[J]. 肝癌电子杂志, 2023, 10(3): 27-30.
[5] Lin, C., Chen, Y., Lo, G., Hsu, Y., Hsu, C., Wu, T., et al. (2020) Comparison of Overall Survival on Surgical Resection versus Transarterial Chemoembolization with or without Radiofrequency Ablation in Intermediate Stage Hepatocellular Carcinoma: A Propensity Score Matching Analysis. BMC Gastroenterology, 20, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[6] 陈家广, 周任, 庞志东. 经导管肝动脉化疗栓塞术用于原发性肝癌治疗的效果研究[J]. 中国社区医师, 2020, 36(8): 14-15.
[7] Galle, P.R., Tovoli, F., Foerster, F., Wörns, M.A., Cucchetti, A. and Bolondi, L. (2017) The Treatment of Intermediate Stage Tumours Beyond TACE: From Surgery to Systemic Therapy. Journal of Hepatology, 67, 173-183. [Google Scholar] [CrossRef] [PubMed]
[8] 司增梅, 王广志, 王建华. 肝癌介入治疗与转移和复发的研究及进展[J]. 中华介入放射学电子杂志, 2015, 3(1): 42-46.
[9] 李猛, 李志艳, 于晓玲. 影像引导射频消融术在肿瘤治疗中的应用进展[J]. 山东医药, 2016, 56(13): 102-105.
[10] 吉婷婷, 史良玉. 射频消融联合TACE对原发性肝癌患者血清甲胎蛋白、基质金属蛋白酶-9水平的影响[J]. 临床医学研究与实践, 2023, 8(19): 80-83.
[11] 尹超. 射频消融术联合经导管动脉化疗栓塞术治疗原发性肝癌的疗效分析[J]. 大医生, 2024, 9(2): 32-34.
[12] Gaba, R.C., Lewandowski, R.J., Hickey, R., Baerlocher, M.O., Cohen, E.I., Dariushnia, S.R., et al. (2016) Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. Journal of Vascular and Interventional Radiology, 27, 457-473. [Google Scholar] [CrossRef] [PubMed]
[13] 徐炜, 梁斌. 肝内胆管癌介入治疗研究进展[J]. 介入放射学杂志, 2025, 34(4): 347-354.
[14] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版) [J]. 中华肝脏病杂志, 2024, 32(7): 581-630.
[15] Berardi, G., Guglielmo, N., Cucchetti, A., et al. (2025) Transarterial Radioembolization Can Downstage Intermediate and Advanced Hepatocellular Carcinoma to Liver Transplantation. Transplantation, 109, e54-e63.
[16] Brown, A.M., Kassab, I., Massani, M., Townsend, W., Singal, A.G., Soydal, C., et al. (2022) TACE versus TARE for Patients with Hepatocellular Carcinoma: Overall and Individual Patient Level Meta Analysis. Cancer Medicine, 12, 2590-2599. [Google Scholar] [CrossRef] [PubMed]

为你推荐